Tranexamic acid in hip fracture surgery: a randomized controlled trial

Area of Science:

• Orthopedic Surgery
• Hematology
• Anesthesiology

Background:

• Hip fracture surgery is linked to significant blood loss.
• Erythrocyte transfusions are common in patients undergoing hip fracture repair.
• Tranexamic acid (TXA) is investigated for its potential to reduce transfusion needs.

Purpose of the Study:

• To evaluate the efficacy of tranexamic acid in reducing erythrocyte transfusions in hip fracture surgery.
• To assess the safety profile of tranexamic acid, specifically focusing on vascular events.

Main Methods:

• A randomized, double-blind study involving patients with hip fractures.
• Patients received either tranexamic acid (15 mg/kg) or a placebo at skin incision and 3 hours later.
• Primary outcome was erythrocyte transfusion up to day 8; safety assessed via vascular events up to 6 weeks.

Main Results:

• The erythrocyte transfusion rate was 42% in the tranexamic acid group versus 60% in the placebo group (P=0.06).
• Vascular event rates were 16% with tranexamic acid and 6% with placebo (P=0.10).
• Meta-analysis indicated TXA reduces transfusions in hip fracture surgery, though less effectively than in arthroplasty.

Conclusions:

• Tranexamic acid demonstrated a trend towards reducing erythrocyte transfusions in hip fracture surgery.
• A potential increase in vascular events was observed, suggesting a possible hypercoagulable state.
• Further safety evaluations are necessary before recommending off-label TXA use in this patient population.